I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Abstract Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunot...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K. Abou-Alfa
Format: Artigo
Langue:Inglês
Publié: SpringerOpen 2018-03-01
Collection:EJNMMI Research
Sujets:
Codrituzumab
I-124
Antibody
Glypican
Hepatocellular
Accès en ligne:http://link.springer.com/article/10.1186/s13550-018-0374-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires